Abstract
Literature shows heterogeneous impact of recommendations to deal with sars-cov-2 infection on AML management during the 2020 Covid-19 pandemic. Available French data only rely on monocentric observations or simulations. From the DATAML cohort, including all AML patients cared for in the centers of South-West France, we compared the characteristics of patients diagnosed in two periods: 2020 and 2015–2019. We use time series approach to describe the monthly proportion of patients with extreme values on hemoglobin, white blood cells, platelets, and blasts counts, as well as early deaths. We found a slight impact of the first lockdown on hemoglobin and platelets, with statistical significance reached only for platelets distribution gap between the two periods. Similar but less marked patterns were found for WBC and blood blasts. These did not translate in terms of early deaths, which was considered to be likely due to a favorable local conjuncture associating a moderate incidence of sars-cov-2 and the absence of bed closing in oncohematology or ICU dedicated to hematology in any centers providing intensive care for AML patients. Yet, our results might still be seen as an insight of what would have happened in less favorable contexts.
Data availability
The DATAML database is coordinated by CR and SB for the eastern sub-cohort and by PYD and AP for the western part. The data are accessible on demand formulated to the coordinators and will be assed according to the DATMAL data sharing agreement. All research teams, whether French or foreign, wishing to use DATAML cohort data must submit a request to Prof. Christian Récher (recher.christian@iuct-oncopole.fr) or Dr. Sarah Bertoli ( [bertoli.sarah@iuct-oncopole.fr](mailto: bertoli.sarah@iuct-oncopole.fr) ) for the LAM Toulouse cohort and/or Prof. Arnaud Pigneux (arnaud.pigneux@chu-bordeaux.fr) and Dr Pierre-Yves Dumas (pierre-yves.dumas@u-bordeaux.fr) for the LAM Bordeaux cohort) in the form of a synopsis that is sufficiently detailed to assess the scientific and methodological quality of the project. The project methodology must be validated by Dr Emilie Bérard (emilie.berard@utoulouse.fr). This may involve using available data and/or collecting additional data for a specific purpose. In the event of additional data collection, the applicant must obtain regulatory approvals relating to data confidentiality (authorization from the CNIL) and/or an ethics committee.
References
Jazieh, A. R. et al. Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO global Oncol. 6, 1461–1471 (2020).
Zaniboni, A. et al. A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic. Cancers (Basel) 12(9), 2452 (2020).
Brissot, E. et al. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 56, 532–535 (2021).
Garnica, M. & Maiolino, A. COVID and hematology: special considerations regarding patient safety, gold standard therapies and safety for health care professionals. Hematol. Transfus. Cell. Therapy. 42 (2), 111–112 (2020).
Wilde, L., Isidori, A., Keiffer, G., Palmisiano, N. & Kasner, M. Caring for AML Patients During the COVID-19 Crisis: An American and Italian Experience. Front. Oncol. 10, 1689 (2020).
Delaye, M., Naoun, N. & Mailly-Giacchetti, L. [SARS-CoV-2 and cancer in France: Resident in oncology on the front line. Testimony of residents in oncology in two French clusters: Grand-Est and Île-de-France]. Bull. Cancer. 107 (6), 633–637 (2020).
Blay, J. Y. et al. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France. ESMO open. 6 (3), 100134 (2021).
Grosclaude, P. et al. COVID-19 impact on the cancer care structuration: example of the multidisciplinary team meeting dedicated to oncology in Occitanie. Bull. Cancer 107(7–8), 730–737 (2020).
Bardet, A. et al. Impact of COVID-19 on healthcare organisation and cancer outcomes. Eur. J. Cancer. 153, 123–132 (2021).
Martín-Moro, F. et al. The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid. Leuk. Res. 101, 106518 (2021).
Pornet, C. et al. Construction of an adaptable European transnational ecological deprivation index: the French version. J. Epidemiol. Community Health. 66 (11), 982–989 (2012).
Quillet, A., Le Stang, N., Meriau, N., Isambert, N. & Defossez, G. Socio-demographic inequalities in stage at diagnosis of lung cancer: A French population-based study. Cancer Epidemiol. 89, 102522 (2024).
Tron, L. et al. Socioeconomic environment and disparities in cancer survival for 19 solid tumor sites: An analysis of the French Network of Cancer Registries (FRANCIM) data. Int. J. Cancer. 144 (6), 1262–1274 (2019).
Berger, E. et al. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients. BMC Cancer. 19 (1), 883 (2019).
Fianu, A. et al. Health impacts of the COVID-19 lockdown measure in a low socio-economic setting: A cross-sectional study on Reunion Island. Int. J. Environ. Res. Public. Health 19(21), 13932 (2022).
Smaïli, S. et al. Dynamics of social inequalities in severe COVID-19 outcomes in metropolitan France from 2020 to 2022. Commun. Med. 5 (1), 516 (2025).
Bouyer, J. Épidémiologie: principes et méthodes quantitatives (Tec & Doc Lavoisier, 2009).
Tedjaseputra, A. et al. Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. Leuk. Lymphoma. 63 (11), 2731–2734 (2022).
Demichelis-Gómez, R. et al. Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries. JCO global Oncol. 7, 577–584 (2021).
Chen, C., Rotter, D., Kiendrebeogo, Z. & Potluri, R. The Impact of COVID-19 on Acute Myeloid Leukemia (AML) Treatment Patterns in the United States: Retrospective Analysis of an Electronic Medical Records (EMR) Database. Blood 138 (Supplement 1), 4139 (2021).
Darques, R., Trottier, J., Gaudin, R. & Ait-Mouheb, N. Clustering and mapping the first COVID-19 outbreak in France. BMC Public. Health. 22 (1), 1279 (2022).
Funding
This work benefited from the financial support from the GIRCI-SOHO to S Bertoli and from the French National League Against Cancer to CERPOP for supporting R Fenni works.
Author information
Authors and Affiliations
Contributions
SL, AP, CR, PYD and SB designed the study. AS and ACDG collected data. AS, ACDG, and EB controlled data quality. SL and RF designed the statistical analyses and analyzed the data. All authors have reviewed and discussed the results. SL RF PYD CR SB wrote the paper and all authors reviewed and corrected the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare the following conflict of interest : PYD declares a consulting or advisory role with Daiichi-Sankyo, Jazz Pharmaceutical, Astellas, Abbvie, Celgene, Janssen, BMS, Gilead, Novartis, and Servier. CR declares a consulting or advisory role with Abbvie, Amgen, Astellas, BMS, Boehringer, Jazz Pharmaceuticals and Servier, and received research funding from Abbvie, Amgen, Astellas, BMS, Iqvia and Jazz Pharmaceuticals. SB declares a consulting or advisory role with Abbvie, Astellas, BMS-Celgene, Jazz Pharmaceuticals and Servier.
Ethics approval
The cohort has been approved by the national ethical authorities (CCTIRS (ref 15.319) and CNIL (ref 915285)).
Patients consent
All patients included in the DATAML cohort received and signed the information notice to express their non-opposition for the use of their data for research.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Lamy, S., Fenni, R., Tavitian, S. et al. Characteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohort. Sci Rep (2026). https://doi.org/10.1038/s41598-026-41768-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-41768-w
